QURE Jan 2025 4.000 put
| Previous close | 0.6000 |
| Open | 0.4500 |
| Bid | 0.3500 |
| Ask | 0.5000 |
| Strike | 4.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.4500 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 64 |
GlobeNewswireuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure’s investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.
Simply Wall St.uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
While it may not be enough for some shareholders, we think it is good to see the uniQure N.V. ( NASDAQ:QURE ) share...
- GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts ass
